|
International generic name
Cinnarizine
Drug form and composition
Tablets. One tablet contains 25 mg Cinnarizine.
Indications
Labyrinthopaty, vascular vestibulopathy, Meniere’s disease; prevention and treatment
of kinesis.
Dosage and administration
Cinnarizin is used orally, before nutrition. In prevention of kinesis - 25 mg,
a half to one hour before the traveling, and after that - 25 mg each 6 hours. For
the treatment of patients with labyrinthopaty, vestibular disorders, and Meniere’s
disease the dose is 75 mg, given three times daily. Maximal dose in adults is 225
mg/24 h. In order to achieve an optimal therapeutic effect Cinnarizin should be
used for several months. In elderly patients the treatment should be started with
low doses (average ½ of the recommended dose), with gradually increase of the daily
dose until the expected therapeutic effect is achieved. In children recommended
daily dose is average ¼ of the daily dose in adults.
Contraindications
Hypersensitivity to the preparation; pregnancy and lactation.
Special warnings and precautions
The preparation should be used with care in: adult patients, children, patients
with family history or clinical manifestations of extrapyramidal disorders. In persons
with hypotension during the treatment the blood pressure should be monitored. In
long-term treatment with Cinnarizin hematology variables, liver and renal laboratory
tests should be monitored. Cinnarizin may cause a somnolence, which reduces the
attention and disturbs the driving capabilities, particularly in the beginning of
the treatment. This requires special care when using the medicine in drivers and
machinery operating persons.
Drug interactions
Cinnarizine may potentiate the effects of the antidepressants and alcohol. Antiacide
medicines and H2-blockers accelerate the resorption of the preparation, reducing
acidity of the stomach fluid. Nootrope agents and vasodilators increase Cinnarizin
effects.
Adverse reactions
At the onset of the treatment the most frequent adverse reactions are: somnolence,
abdominal pain and discomfort, which usually are transitory and resolve after the
dose adjustment. Hypersensitivity reactions usually affect the skin. Cinnarizin
may intensify the trend to hypotension reactions or preexistent hypotension, xerostomia,
appetite increase. The most serious adverse reactions are extrapyramidal disorders
(tremor, disorientation, balance disorders), including Parkinson’s syndrome. Cinnarizin
may cause false doping-positive reactions in sportsmen. Due to its antihistamine
effect Cinnarizin may lead to false - negative result in intradermal hypersensitivity
testing. In this reason the treatment with the preparation should be discontinued
at least 4 days before the testing.
Pharmacological mechanisms
Cinnarizin improves the brain and peripheral microcirculation, antagonizing vascular
effects of the endogenous monoamines and oligopeptides, and blocking the calcium
influx in the myocytes of the vessel wall. The preparation possesses a high affinity
to the vessel smooth muscle cells in the brain. It reduces the erythrocyte deformity
and improves rheology of the blood. Improves the cell resistance to hypoxia. Cinnarizin
has no cardiodepressive effect. Reduces nystagmus and other vestibular disorders,
reduces the labyrinth irritability. Exerts certain antihystamine action.
Supplied
50 tablets of 25 mg.
Expiry
3 years.
|